StreetInsider.com News Articles

Form NT 10-K VivoSim Labs, INC. For: Mar 31

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706413.html

Form NT 10-K VivoSim Labs, INC. For: Mar 31

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706413.html

VivoSim presents liver toxicity data at European toxicology conference

Mon, 29 Jun 2026 08:05:49 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced that data from its 3D human tissue models will be featured in two presentations at the European Society of Toxicology's annual conference, taking place June 29 through July 2, 2026, in Maastricht, the Netherlands.

According to the company's press release, VivoSim's NAMkind™ Liver model achieved 91% predictive accuracy when benchmarked against a clinical dataset of 92 small-molecule compounds, with 90% sensitivity, 95% specificity, and 99% precision under repeat-dose conditions. The company states that traditional animal models and conventional methods provide 50–65% sensitivity for the same compounds, while its models produce fewer than 5% false positives

VivoSim presents liver toxicity data at European toxicology conference

Mon, 29 Jun 2026 08:05:49 -0400

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

Mon, 29 Jun 2026 08:05:00 -0400

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology’s annual conference.

The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

Mon, 29 Jun 2026 08:05:00 -0400

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)

The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver

VivoSim develops AI tool to predict drug-induced diarrhea

Tue, 28 Apr 2026 08:05:37 -0400

VivoSim Labs Inc. (NASDAQ: VIVS) announced the availability of an AI prediction tool that uses human intestinal tissue models to predict whether drug compounds may cause diarrhea in patients. The tool combines the company's NAMkind intestinal models with machine learning analytics to identify drug-induced disruptions to intestinal function.

The AI model was trained using data from dozens of compounds tested in VivoSim's 3D tissue-based assays. The company reported the model achieved 96% predictive accuracy for potential diarrhea occurrence. The system, called VitroSense, measures multiple data endpoints from NAMkind intestine assays and feeds this information into the AI model to assess diarrhea

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing